PRESS RELEASE published on 11/05/2025 at 13:46, 4 months 25 days ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 10/10/2025 at 22:16, 5 months 21 days ago La FDA approuve UZEDY pour le traitement du trouble bipolaire de type I chez l'adulte Approbation De La FDA Traitement De Santé Mentale UZEDY Trouble Bipolaire I Risperidone
BRIEF published on 10/10/2025 at 22:16, 5 months 21 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 5 months 21 days ago Informations privilégiées / Autres communiqués La FDA approuve l’extension d’indication de UZEDY® pour le traitement de patients atteints de trouble bipolaire de type I par Teva Pharmaceuticals et Medincell FDA Medincell Teva Pharmaceuticals UZEDY Traitement Bipolaire
PRESS RELEASE published on 10/10/2025 at 22:11, 5 months 21 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 6 months 13 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
BRIEF published on 09/17/2025 at 14:05, 6 months 13 days ago Medincell et Teva présentent les données de phase 3 sur l'olanzapine LAI Essai De Phase 3 Traitement De La Schizophrénie Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 6 months 13 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 6 months 13 days ago Informations privilégiées / Autres communiqués Teva et Medincell présenteront les résultats de phase 3 de l'Olanzapine LAI à Psych Congress 2025, préparant le lancement du traitement de la schizophrénie avec Teva Schizophrénie Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 6 months 19 days ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
Published on 04/01/2026 at 08:05, 2 hours 51 minutes ago Tocvan Discovers New Gold-Silver Zone 1,600 Meters From Main Zone at South Block Gran Pilar; First Aggressive Step-Out Drilling Intersects Mineralization From Surface
Published on 04/01/2026 at 08:00, 2 hours 56 minutes ago Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 04/01/2026 at 04:06, 6 hours 50 minutes ago Jaguar Mining Reports Financial Results for the Fourth Quarter and Full Year 2025
Published on 04/01/2026 at 03:57, 6 hours 59 minutes ago NXT Energy Solutions Announces 2025 Year-End Results
Published on 04/01/2026 at 10:10, 45 minutes ago LITFINCON Announces European Debut: Global Litigation Finance Conference Series Comes to Amsterdam
Published on 04/01/2026 at 10:00, 56 minutes ago MS Industrie AG acquires real estate property in Trossingen and reports key figures for fiscal year 2025, along with a current business update and outlook for 2026
Published on 04/01/2026 at 09:05, 1 hour 50 minutes ago Solar Power to Go: Jackery Unveils SolarSaga 40 Air, the Next Generation of Compact Foldable Solar Panels
Published on 04/01/2026 at 09:05, 1 hour 50 minutes ago Rockwell Automation Announces ROKStudios Video Series Launches a New Season Exploring the Journey from Automation to Autonomy
Published on 04/01/2026 at 09:00, 1 hour 55 minutes ago Original-Research: LAIQON AG (von NuWays AG): BUY
Published on 04/01/2026 at 08:00, 2 hours 56 minutes ago Transfert du contrat de liquidité aupres de Natixis Oddo BHF
Published on 04/01/2026 at 08:00, 2 hours 56 minutes ago Résultats annuels 2025 - ANR par action en hausse de + 8,1 % à 97,10 € - Fonds propres consolidés : 740 M€
Published on 03/31/2026 at 20:08, 14 hours 48 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 15 hours 50 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 15 hours 50 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
